Does the media favor SANA or RNAC?

In the previous week, Sana Biotechnology had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 6 mentions for Sana Biotechnology and 2 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.43 beat Sana Biotechnology's score of 0.54 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RNAC or ANNX?

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 2 articles in the media. Annexon's average media sentiment score of 1.45 beat Cartesian Therapeutics' score of 1.43 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RNAC or AVTX?

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 2 articles in the media. Cartesian Therapeutics' average media sentiment score of 1.43 beat Avalo Therapeutics' score of 1.28 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GERN or RNAC?

In the previous week, Geron had 1 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Geron and 2 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.43 beat Geron's score of 1.01 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cartesian Therapeutics (RNAC) Competitors

$6.36 -0.22 (-3.27%)

As of 03:51 PM Eastern

Compare

RNAC vs. SANA, ANNX, AVTX, CADL, and GERN

Should you buy Cartesian Therapeutics stock or one of its competitors? Cartesian Therapeutics's main competitors and comparable companies include Sana Biotechnology (SANA), Annexon (ANNX), Avalo Therapeutics (AVTX), Candel Therapeutics (CADL), and Geron (GERN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cartesian Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cartesian Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Cartesian Therapeutics	$2.80M	70.98	-$130.30M	-$5.94	N/A

Sana Biotechnology presently has a consensus price target of $9.33, indicating a potential upside of 287.28%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 396.19%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Sana Biotechnology has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

Sana Biotechnology has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

In the previous week, Sana Biotechnology had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 6 mentions for Sana Biotechnology and 2 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.43 beat Sana Biotechnology's score of 0.54 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Cartesian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sana Biotechnology beats Cartesian Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Annexon?

Cartesian Therapeutics (NASDAQ:RNAC) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Cartesian Therapeutics currently has a consensus price target of $32.60, indicating a potential upside of 396.19%. Annexon has a consensus price target of $15.29, indicating a potential upside of 299.10%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Cartesian Therapeutics is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cartesian Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	70.98	-$130.30M	-$5.94	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

87.0% of Cartesian Therapeutics shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 10.3% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cartesian Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Annexon has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Annexon has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
Annexon	N/A	-106.15%	-79.82%

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 2 articles in the media. Annexon's average media sentiment score of 1.45 beat Cartesian Therapeutics' score of 1.43 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cartesian Therapeutics beats Annexon on 8 of the 13 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Avalo Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Avalo Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Cartesian Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 2 articles in the media. Cartesian Therapeutics' average media sentiment score of 1.43 beat Avalo Therapeutics' score of 1.28 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cartesian Therapeutics currently has a consensus target price of $32.60, indicating a potential upside of 396.19%. Avalo Therapeutics has a consensus target price of $45.10, indicating a potential upside of 275.52%. Given Cartesian Therapeutics' higher probable upside, research analysts clearly believe Cartesian Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Avalo Therapeutics has lower revenue, but higher earnings than Cartesian Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	70.98	-$130.30M	-$5.94	N/A
Avalo Therapeutics	$60K	10,734.94	-$78.26M	-$4.37	N/A

Summary

Avalo Therapeutics beats Cartesian Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Candel Therapeutics currently has a consensus price target of $20.14, indicating a potential upside of 117.29%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 396.19%. Given Cartesian Therapeutics' higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Candel Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

In the previous week, Cartesian Therapeutics had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 2 mentions for Cartesian Therapeutics and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 1.79 beat Cartesian Therapeutics' score of 1.43 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Candel Therapeutics	Very Positive
Cartesian Therapeutics	Positive

Candel Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Cartesian Therapeutics	$2.80M	70.98	-$130.30M	-$5.94	N/A

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Candel Therapeutics has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Summary

Cartesian Therapeutics beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Geron?

Geron (NASDAQ:GERN) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Geron had 1 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Geron and 2 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.43 beat Geron's score of 1.01 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a net margin of -34.17% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

73.7% of Geron shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Geron has higher revenue and earnings than Cartesian Therapeutics. Geron is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.19	-$83.50M	-$0.11	N/A
Cartesian Therapeutics	$2.80M	70.98	-$130.30M	-$5.94	N/A

Geron has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Geron presently has a consensus price target of $4.00, suggesting a potential upside of 233.33%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 396.19%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Cartesian Therapeutics beats Geron on 9 of the 15 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAC vs. The Competition

Export

Metric	Cartesian Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$192.39M	$3.90B	$7.29B	$12.91B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-1.07	12.96	275.68	25.25
Price / Sales	68.71	1,151.37	562.78	78.51
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	-1.31	16.59	10.54	5.92
Net Income	-$130.30M	-$22.69M	$3.50B	$381.16M
7 Day Performance	-4.79%	-6.38%	-4.13%	-4.32%
1 Month Performance	-20.90%	-14.15%	-8.51%	-7.19%
1 Year Performance	-32.48%	6.41%	2.12%	-4.99%

Cartesian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAC Cartesian Therapeutics	2.1824 of 5 stars	$6.36 -3.2%	$32.60 +412.6%	-30.8%	$192.39M	$2.80M	N/A	75	Positive News
SANA Sana Biotechnology	3.4066 of 5 stars	$2.75 -4.5%	$9.33 +239.4%	-44.5%	$862.16M	N/A	N/A	142	News Coverage
ANNX Annexon	3.8079 of 5 stars	$4.03 -4.0%	$15.29 +279.3%	+27.2%	$796.23M	N/A	N/A	92	Positive News
AVTX Avalo Therapeutics	2.9009 of 5 stars	$13.59 -6.9%	$45.10 +231.9%	-12.1%	$783.00M	$59K	N/A	33	News Coverage
CADL Candel Therapeutics	2.8708 of 5 stars	$9.87 -3.5%	$20.14 +104.1%	+43.3%	$782.79M	N/A	N/A	55

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAC) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. SANA, ANNX, AVTX, CADL, and GERN

How does Cartesian Therapeutics compare to Sana Biotechnology?

Summary

How does Cartesian Therapeutics compare to Annexon?

Summary

How does Cartesian Therapeutics compare to Avalo Therapeutics?

Summary

How does Cartesian Therapeutics compare to Candel Therapeutics?

Summary

How does Cartesian Therapeutics compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. SANA, ANNX, AVTX, CADL, and GERN

How does Cartesian Therapeutics compare to Sana Biotechnology?

Do insiders & institutionals believe in SANA or RNAC?

Which has stronger earnings and valuation, SANA or RNAC?

Do analysts recommend SANA or RNAC?

Is SANA or RNAC more profitable?

Which has more volatility and risk, SANA or RNAC?

Does the media favor SANA or RNAC?

Summary

How does Cartesian Therapeutics compare to Annexon?

Do analysts rate RNAC or ANNX?

Which has stronger earnings and valuation, RNAC or ANNX?

Do institutionals & insiders believe in RNAC or ANNX?

Which has more volatility and risk, RNAC or ANNX?

Is RNAC or ANNX more profitable?

Does the media refer more to RNAC or ANNX?

Summary

How does Cartesian Therapeutics compare to Avalo Therapeutics?

Do insiders & institutionals believe in RNAC or AVTX?

Is RNAC or AVTX more profitable?

Which has more volatility and risk, RNAC or AVTX?

Does the media refer more to RNAC or AVTX?

Do analysts prefer RNAC or AVTX?

Which has stronger valuation & earnings, RNAC or AVTX?

Summary

How does Cartesian Therapeutics compare to Candel Therapeutics?

Do analysts prefer CADL or RNAC?

Is CADL or RNAC more profitable?

Does the media favor CADL or RNAC?

Which has preferable valuation & earnings, CADL or RNAC?

Do insiders and institutionals hold more shares of CADL or RNAC?

Which has more volatility & risk, CADL or RNAC?

Summary

How does Cartesian Therapeutics compare to Geron?

Does the media favor GERN or RNAC?

Is GERN or RNAC more profitable?

Do institutionals and insiders have more ownership in GERN or RNAC?

Which has better valuation & earnings, GERN or RNAC?

Which has more volatility and risk, GERN or RNAC?

Do analysts prefer GERN or RNAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools